Investment
Features
FeesSafety
Academy
More
Pluang+

Regeneron's melanoma drug combo fails phase 3 trial, shares dip but long-term outlook remains positive.

Market News
18 May 2026
Seeking Alpha
View Source
Neutral
pluang ai news

Regeneron Pharmaceuticals faced a setback as its drugs fianlimab and Libtayo failed to meet endpoints in a phase 3 trial for first-line metastatic melanoma, causing shares to drop. However, this failure is not seen as critical for Regeneron's long-term value since fianlimab-based combinations were not central to its growth strategy. The company is still positioned for success due to its strong pipeline, balance sheet, and potential for growth. Key risks include possible further weakness in its Eylea franchise and other clinical trial disappointments.

More News (REGN)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App